QR Pharma Awarded SBIR Grant by National Institute on Aging/National Institutes of Health (NIH) to Test Posiphen(R) and Metabolites in Various Models  
9/21/2010 10:06:15 AM

RADNOR, Pa.--(BUSINESS WIRE)--QR Pharma, Inc. (QR), a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment and Alzheimer’s disease and the Medical University of South Carolina (MUSC) announced today that they received a Small Business Innovation Research (SBIR) phase I grant in the amount of $220,000 to study Posiphen® and its metabolites in cell culture and in transgenic Alzheimer mice.